ArticleOncogene2006
Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland.
Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Cyclin E in normal physiology and disease states.Trends in cell biology · 2021Review
- Loss of Fbxw7 triggers mammary tumorigenesis associated with E2F/c-Myc activation and Trp53 mutation.Neoplasia (New York, N.Y.) · 2020Article
- Cyclin E Overexpression in Human Mammary Epithelial Cells Promotes Epithelial Cancer-Specific Copy Number Alterations.iScience · 2019Article
- Insertional mutagenesis using the Sleeping Beauty transposon system identifies drivers of erythroleukemia in mice.Scientific reports · 2019Article
- The PP2A-B56 Phosphatase Opposes Cyclin E Autocatalytic Degradation via Site-Specific Dephosphorylation.Molecular and cellular biology · 2017Article
- Cell cycle proteins as promising targets in cancer therapy.Nature reviews. Cancer · 2017Review
- Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.Cancer research · 2014Article
- Chemotherapy induced microsatellite instability and loss of heterozygosity in chromosomes 2, 5, 10, and 17 in solid tumor patients.Cancer cell international · 2014Article
- Signaling pathways that control cell proliferation.Cold Spring Harbor perspectives in biology · 2013Review
- Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier triggered by activated oncoproteins.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- An integrated view of cyclin E function and regulation.Cell cycle (Georgetown, Tex.) · 2012Article
- Hypoxia-inducible factor 1 is activated by dysregulated cyclin E during mammary epithelial morphogenesis.Molecular and cellular biology · 2011Article
- Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines.Cell cycle (Georgetown, Tex.) · 2010Article
- MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7.The Journal of biological chemistry · 2010Article
- Reduced spermatogonial proliferation and decreased fertility in mice overexpressing cyclin E in spermatogonia.Cell cycle (Georgetown, Tex.) · 2010Article
- The ubiquitous nature of cancer: the role of the SCF(Fbw7) complex in development and transformation.Oncogene · 2010Review
- Mitotic chromosome condensation mediated by the retinoblastoma protein is tumor-suppressive.Genes & development · 2010Article
- Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2010Article
- Article
- Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc.Molecular and cellular biology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Deregulation of cyclin E expression and/or high levels have been reported in a variety of tumors and have been used as indicators of poor prognosis. Although the role that cyclin E plays in tumorigenesis remains unclear, there is evidence that it confers genomic instability when deregulated in cultured cells. Here we show that deregulated expression of a hyperstable allele of cyclin E in mice heterozygous for p53 synergistically increases mammary tumorigenesis more than that in mice carrying either of these markers individually. Most tumors and tumor-derived cell lines demonstrated loss of p53 heterozygosity. Furthermore, this tumor susceptibility is related to the number of times the transgene is induced indicating that it is directly attributable to the expression of the cyclin E transgene. An indirect assay indicates that loss of p53 function is an early event occurring in the mammary epithelia of midlactation mammary glands in which cyclin E is deregulated long before evidence of malignancy. These data support the hypothesis that deregulated expression of cyclin E stimulates p53 loss of heterozygosity by promoting genomic instability and provides specific evidence for this in vivo. Cyclin E deregulation and p53 loss are characteristics often observed in human breast carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.